Merging new-age biomarkers and nanodiagnostics for precision prostate cancer management
The accurate identification and stratified treatment of clinically significant early-stage
prostate cancer have been ongoing concerns since the outcomes of large international …
prostate cancer have been ongoing concerns since the outcomes of large international …
Prostate cancer liquid biopsy biomarkers' clinical utility in diagnosis and prognosis
Simple Summary In prostate cancer, overdiagnosis and overtreatment is a common problem
for clinicians. Accurate diagnosis and prognosis are essential to avoid unnecessary biopsy …
for clinicians. Accurate diagnosis and prognosis are essential to avoid unnecessary biopsy …
[HTML][HTML] The long non-coding RNA PCA3: an update of its functions and clinical applications as a biomarker in prostate cancer
AEG Lemos, A da Rocha Matos, LB Ferreira - Oncotarget, 2019 - ncbi.nlm.nih.gov
Abstract Prostate cancer antigen 3 (PCA3) is an overexpressed prostate long non-coding
RNA (lncRNA), transcribed from an intronic region at the long arm of human chromosome …
RNA (lncRNA), transcribed from an intronic region at the long arm of human chromosome …
[HTML][HTML] Biomarkers for detection of clinically significant prostate cancer: contemporary clinical data and future directions
Use of serum prostate-specific antigen (PSA) testing for early detection of prostate cancer
appears to reduce cancer-specific mortality. Due to the limited specificity of PSA for clinically …
appears to reduce cancer-specific mortality. Due to the limited specificity of PSA for clinically …
New biomarkers for diagnosis and prognosis of localized prostate cancer
DA Chistiakov, VA Myasoedova, AV Grechko… - Seminars in cancer …, 2018 - Elsevier
The diagnostics and management of localized prostate cancer is complicated because of
cancer heterogeneity and differentiated progression in various subgroups of patients. As a …
cancer heterogeneity and differentiated progression in various subgroups of patients. As a …
Metastatic castration-resistant prostate cancer: insights on current therapy and promising experimental drugs
S Ferretti, C Mercinelli, L Marandino… - … and Reports in …, 2023 - Taylor & Francis
The therapeutic landscape of metastatic hormone sensitive and metastatic castration-
resistant prostate cancer (mCRPC) is rapidly changing. We reviewed the current treatment …
resistant prostate cancer (mCRPC) is rapidly changing. We reviewed the current treatment …
Urinary biomarkers in prostate cancer detection and monitoring progression
Prostate cancer (CaP) is the most common cancer in men and the second leading cause of
cancer deaths in males in Australia. Although serum prostate-specific antigen (PSA) has …
cancer deaths in males in Australia. Although serum prostate-specific antigen (PSA) has …
Urinary RNA-based biomarkers for prostate cancer detection
F Martignano, L Rossi, A Maugeri, V Gallà… - Clinica Chimica …, 2017 - Elsevier
Prostate cancer (PCa) is the commonest malignancy in the male population worldwide.
Serum prostate specific antigen (PSA) test is the most important biomarker for the detection …
Serum prostate specific antigen (PSA) test is the most important biomarker for the detection …
Urinary MyProstateScore (MPS) to rule out clinically-significant cancer in men with equivocal (PI-RADS 3) multiparametric MRI: addressing an unmet clinical need
Objective To evaluate the complementary value of urinary MyProstateScore (MPS) testing
and multiparametric MRI (mpMRI) and assess outcomes in patients with equivocal mpMRI …
and multiparametric MRI (mpMRI) and assess outcomes in patients with equivocal mpMRI …
MyProstateScore in men considering repeat biopsy: validation of a simple testing approach
Background Men with persistent risk of Grade Group (GG)≥ 2 cancer after a negative biopsy
present a unique clinical challenge. The validated MyProstateScore test is clinically …
present a unique clinical challenge. The validated MyProstateScore test is clinically …